{
  "main_header": {
    "sid": 1288844,
    "name": "Monte Rosa Therapeutics, Inc.",
    "stock_name": "Monte Rosa Therapeutics, Inc.",
    "full_name": "Monte Rosa Therapeutics, Inc.",
    "name_url": "stocks-analysis/monte-rosa-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "17.26",
    "chg": 1.85,
    "chgp": "12.01%",
    "dir": 1,
    "prev_price": "15.41",
    "mcapval": "296.44",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US61225M1027",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.32 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/monte-rosa-therapeutics-inc-1288844-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Monte Rosa Therapeutics, Inc. Experiences Valuation Adjustment Amid Strong Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/monte-rosa-therapeutics-valuation-grade-changes-from-fair-to-expensive-amid-price-decline-3686371",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/MonteRosaTherap_valuationdot_3686371.png",
        "date": "2025-11-10 16:25:52",
        "description": "Monte Rosa Therapeutics, Inc. has recently adjusted its valuation, with its current price at $12.31. Over the past year, the company has outperformed the S&P 500, achieving a 29.17% return. Key financial metrics include a P/E ratio of 50 and a ROCE of 4.53%, indicating its unique industry position."
      },
      {
        "title": "Monte Rosa Therapeutics Hits Day High with 8.42% Surge in Stock Price",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/monte-rosa-therapeutics-hits-day-high-with-842-surge-in-stock-price-3680276",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/MonteRosaTherap_priceRelatedfactors_3680276.png",
        "date": "2025-11-07 16:42:48",
        "description": "Monte Rosa Therapeutics, Inc. saw a notable increase in its stock price on November 6, 2025, reaching an intraday high. The company has demonstrated impressive financial growth, with significant increases in net sales and operating cash flow, alongside strong institutional holdings, reflecting confidence in its market position."
      },
      {
        "title": "Monte Rosa Therapeutics Hits New 52-Week High of $13.59",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/monte-rosa-therapeutics-hits-new-52-week-high-of-1359-3680204",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/MonteRosaTherap_priceRelatedfactors_3680204.png",
        "date": "2025-11-07 16:12:57",
        "description": "Monte Rosa Therapeutics, Inc. achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has experienced significant stock price growth and impressive net sales increases, maintaining positive results for five consecutive quarters and showcasing its competitive position in the market."
      },
      {
        "title": "Monte Rosa Therapeutics Hits New 52-Week High of $13.22",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/monte-rosa-therapeutics-hits-new-52-week-high-of-1322-3667347",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/MonteRosaTherap_priceRelatedfactors_3667347.png",
        "date": "2025-11-03 17:18:16",
        "description": "Monte Rosa Therapeutics, Inc. has achieved a new 52-week high, reflecting significant growth in the Pharmaceuticals & Biotechnology sector. The company reported a 394.01% increase in net sales, positive results for five consecutive quarters, and a strong financial position with high institutional holdings, indicating investor confidence."
      },
      {
        "title": "Monte Rosa Therapeutics Hits New 52-Week High of $13.10",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/monte-rosa-therapeutics-hits-new-52-week-high-of-1310-3662039",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/MonteRosaTherap_priceRelatedfactors_3662039.png",
        "date": "2025-10-31 16:29:56",
        "description": "Monte Rosa Therapeutics, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has experienced significant growth in net sales and maintained positive results for five consecutive quarters, supported by high institutional ownership and solid financial metrics."
      },
      {
        "title": "Monte Rosa Therapeutics Hits New 52-Week High of $12.97",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/monte-rosa-therapeutics-hits-new-52-week-high-of-1297-3659216",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/MonteRosaTherap_priceRelatedfactors_3659216.png",
        "date": "2025-10-30 18:52:53",
        "description": "Monte Rosa Therapeutics, Inc. has achieved a new 52-week high, reflecting strong performance in the pharmaceuticals and biotechnology sector. The company has experienced substantial growth in stock performance and net sales over the past year, maintaining positive results for five consecutive quarters and demonstrating robust financial metrics."
      },
      {
        "title": "Monte Rosa Therapeutics, Inc. Experiences Valuation Adjustment Amid Strong Performance Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/monte-rosa-therapeutics-valuation-grade-downgraded-from-attractive-to-fair-3649150",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/MonteRosaTherap_valuationdot_3649150.png",
        "date": "2025-10-27 16:15:30",
        "description": "Monte Rosa Therapeutics, Inc. has recently adjusted its valuation, with its current price at $11.14, reflecting a significant annual performance increase of 128.75%. Key financial metrics include a P/E ratio of 50 and a price-to-book value of 1.12, positioning the company favorably compared to its peers in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Is Monte Rosa Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-monte-rosa-therapeutics-inc-overvalued-or-undervalued-3638045",
        "imagepath": "",
        "date": "2025-10-21 12:14:08",
        "description": "As of 17 October 2025, the valuation grade for Monte Rosa Therapeutics, Inc. has moved from very attractive to fair. Based on the current metrics, the company appears to be fairly valued. The P/E ratio stands at 50, while the Price to Book Value is 1.12, and the PEG Ratio is 0.48, indicating that the stock may not be significantly undervalued despite its previous attractive rating.\n\nIn comparison with peers, Monte Rosa's P/E ratio of 12.27 is notably higher than MeiraGTx Holdings Plc, which has a P/E of -3.82, and 23andMe Holding Co., which has a P/E of -0.75, suggesting that Monte Rosa is relatively more valued in the market. Over the past year, Monte Rosa has delivered a return of 83.06%, significantly outperforming the S&P 500's return of 14.08%, reinforcing the notion that the stock is currently fairly valued in light of its recent performance...."
      },
      {
        "title": "Monte Rosa Therapeutics, Inc. Experiences Valuation Adjustment Amidst Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/monte-rosa-therapeutics-valuation-grade-downgraded-from-very-attractive-to-fair-3641170",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/MonteRosaTherap_valuationdot_3641170.png",
        "date": "2025-10-20 17:36:14",
        "description": "Monte Rosa Therapeutics, Inc. has recently adjusted its valuation, showing a P/E ratio of 50 and a price-to-book value of 1.12. The company has outperformed the S&P 500 year-to-date with a return of 44.81%, highlighting its distinct position in the Pharmaceuticals & Biotechnology sector compared to peers."
      }
    ],
    "total": 21,
    "sid": "1288844",
    "stock_news_url": "https://www.marketsmojo.com/news/monte-rosa-therapeutics-inc-1288844"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Monte Rosa Therapeutics, Inc. Experiences Valuation Adjustment Amid Strong Market Performance

2025-11-10 16:25:52

Monte Rosa Therapeutics, Inc. has recently adjusted its valuation, with its current price at $12.31. Over the past year, the company has outperformed the S&P 500, achieving a 29.17% return. Key financial metrics include a P/E ratio of 50 and a ROCE of 4.53%, indicating its unique industry position.

Read More

Monte Rosa Therapeutics Hits Day High with 8.42% Surge in Stock Price

2025-11-07 16:42:48

Monte Rosa Therapeutics, Inc. saw a notable increase in its stock price on November 6, 2025, reaching an intraday high. The company has demonstrated impressive financial growth, with significant increases in net sales and operating cash flow, alongside strong institutional holdings, reflecting confidence in its market position.

Read More

Monte Rosa Therapeutics Hits New 52-Week High of $13.59

2025-11-07 16:12:57

Monte Rosa Therapeutics, Inc. achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has experienced significant stock price growth and impressive net sales increases, maintaining positive results for five consecutive quarters and showcasing its competitive position in the market.

Read More

Monte Rosa Therapeutics Hits New 52-Week High of $13.22

2025-11-03 17:18:16

Monte Rosa Therapeutics, Inc. has achieved a new 52-week high, reflecting significant growth in the Pharmaceuticals & Biotechnology sector. The company reported a 394.01% increase in net sales, positive results for five consecutive quarters, and a strong financial position with high institutional holdings, indicating investor confidence.

Read More

Monte Rosa Therapeutics Hits New 52-Week High of $13.10

2025-10-31 16:29:56

Monte Rosa Therapeutics, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has experienced significant growth in net sales and maintained positive results for five consecutive quarters, supported by high institutional ownership and solid financial metrics.

Read More

Monte Rosa Therapeutics Hits New 52-Week High of $12.97

2025-10-30 18:52:53

Monte Rosa Therapeutics, Inc. has achieved a new 52-week high, reflecting strong performance in the pharmaceuticals and biotechnology sector. The company has experienced substantial growth in stock performance and net sales over the past year, maintaining positive results for five consecutive quarters and demonstrating robust financial metrics.

Read More

Monte Rosa Therapeutics, Inc. Experiences Valuation Adjustment Amid Strong Performance Metrics

2025-10-27 16:15:30

Monte Rosa Therapeutics, Inc. has recently adjusted its valuation, with its current price at $11.14, reflecting a significant annual performance increase of 128.75%. Key financial metrics include a P/E ratio of 50 and a price-to-book value of 1.12, positioning the company favorably compared to its peers in the Pharmaceuticals & Biotechnology sector.

Read More

Is Monte Rosa Therapeutics, Inc. overvalued or undervalued?

2025-10-21 12:14:08

As of 17 October 2025, the valuation grade for Monte Rosa Therapeutics, Inc. has moved from very attractive to fair. Based on the current metrics, the company appears to be fairly valued. The P/E ratio stands at 50, while the Price to Book Value is 1.12, and the PEG Ratio is 0.48, indicating that the stock may not be significantly undervalued despite its previous attractive rating. In comparison with peers, Monte Rosa's P/E ratio of 12.27 is notably higher than MeiraGTx Holdings Plc, which has a P/E of -3.82, and 23andMe Holding Co., which has a P/E of -0.75, suggesting that Monte Rosa is relatively more valued in the market. Over the past year, Monte Rosa has delivered a return of 83.06%, significantly outperforming the S&P 500's return of 14.08%, reinforcing the notion that the stock is currently fairly valued in light of its recent performance....

Read More

Monte Rosa Therapeutics, Inc. Experiences Valuation Adjustment Amidst Competitive Market Landscape

2025-10-20 17:36:14

Monte Rosa Therapeutics, Inc. has recently adjusted its valuation, showing a P/E ratio of 50 and a price-to-book value of 1.12. The company has outperformed the S&P 500 year-to-date with a return of 44.81%, highlighting its distinct position in the Pharmaceuticals & Biotechnology sector compared to peers.

Read More

View All News